AI Bias Analysis
4 models · Takes ~15 seconds
(MedPage Today) -- SAN DIEGO -- Injecting the PD-1 inhibitor nivolumab (Opdivo) directly into high-risk oral precancers proved safe and reduced lesion size in the vast majority of patients enrolled in a small phase I study, allowing some to avoid...
Source
MedPage Today
Opens original article in a new tab
Kennedy continues to make waves across health care, but he's pulled back on a number of core MAHA issues.
(MedPage Today) -- U.S. health officials stopped the publication of a study on whether the COVID-19 vaccine was keeping adults from becoming sick enough to have to go to the hospital. An HHS spokesman on Wednesday confirmed the decision to halt...
(MedPage Today) -- Oral nirmatrelvir-ritonavir (Paxlovid) failed to spare COVID-19-vaccinated individuals from the worst outcomes if they got sick, though it may have helped speed recovery time and cut viral loads, according to two community-based...
(MedPage Today) -- The interleukin-6 (IL-6) inhibitor satralizumab (Enspryng) met its primary endpoint in the phase III METEOROID trial of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Satralizumab reduced the risk of...
